1Semiqlazov V, Eiermann W, Manikhas A, et al. Surgical aspect in NOAH phase I~ trial (neoadjuvant trastuzumab in her2-positive locally advanced breast cancer)[J]. Eur J Cancer Suppl, 2008, 6(2): 169-170.
2Pickels MD, Lowry M, Manton DJ, et al. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to breast neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2005, 92(1): 1-10.
3Mazouni C, Hall A, Broglio K, et al. Kinetics of Serum HER-2/neu Changes in Patients With HER-2-Positive Primary Breast Cancer After Initiation of Primary Chemotherapy[J]. Cancer, 2007, 109(3): 496-501.
4Lee DH, Han JY, Kim HT, et al. Gefitinib is of more benefit in chemotherapy-naive patient with good performance status andadenocarcinoms histology:Retrospective analysis of 575 Korean patients [J]. Lung Cancer, 2006, 53(3): 339-345.
5Suzuki R, Hasegawa Y, Baba K, et al. A phase II study of single-agent gefitinib as first -line therapy in patient with stage IV non-small-cell lung cancer [J]. Br J Cancer, 2006, 94(117): 1599-1603.
6Wissner A, Mansour TS. The development of HKI-272 and related compounds for the treatment of cancer [J]. Arch Pharm (Weinheim), 2008, 341(8): 465-477.
7Miller KD, Chap LI, Holmes FA, et al. Randomized phase trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer [J]. J Clin Oncol, 2005, 23(4): 792-799.
8Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer [J]. New Engl J Med, 2007, 357(26): 2666-2676.
9Hilles JJ , Kolessar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma [J]. Am J Heath SystPharm, 2008,65(2): 123-131.
10Hofheinz RD, Horisberger K, Woernle C, et al. Phase I trial of eetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2006, 66(5): 1384-1390.
